Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1149 - Circulating tumour DNA experience in patients with Cancer of Unknown Primary

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Tumour Site

Carcinoma of Unknown Primary Site (CUP)

Presenters

Helen Winter

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

H. Winter1, I. Faull2, P. Bains1, C. Murias1, M. Kushnir1, M.D. Forster3, A. Kulkarni4, D. Moore3, C. Swanton5, K. Shiu3, H. Arkenau6

Author affiliations

  • 1 Early Phase Trials, Sarah Cannon Research Institute, W1 - London/GB
  • 2 Business Development & Medical Affairs, Guardant Health, 08028 - Barcelona/ES
  • 3 Medical Oncology, University College London Cancer Institute, WC1E6BT - London/GB
  • 4 Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, SE1 - London/GB
  • 5 Translational Cancer Therapeutics, The Francis Crick Institute, NW1 1AT - London/GB
  • 6 Scri, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
More

Resources

Abstract 1149

Background

Improving the outcome for patients diagnosed with Cancer of Unknown Primary (CUP) is an unmet clinical need where survival is usually less than 1 year. Molecular characterisation of the disease may have diagnostic and therapeutic implications. The circulating tumour DNA test - Guardant 360™ is designed to detect gene alterations with a range of clinical utility.

Methods

Twenty-five patients were referred to Sarah Cannon Research Institute for the Guardant 360™ test. Panel version 2.10 reports single nucleotide variants in 73 genes, gene copy number amplifications in 18 genes, fusions/rearrangements in 6 genes as well as indels in 23 genes. The panel covers all NCCN somatic mutations. Digital SequencingTM technology essentially eliminates false positives allowing sequencing of targeted regions at very low DNA concentrations. Variants of unknown significance (VUS) were also measured. All patients were discussed at our institutional Genomics Review Board.

Results

Twenty-five patients (14 female; 11 male) were recruited from 24 August 2017 to 17 April 2018. Median age was 67 years (range 27-76). Main sites of disease were: lymph nodes (8); pelvis (8); liver (6); bone (3) and adrenal glands (2). The median turnaround time (TAT) from sample collection to report was 10 days (range 6-15). Seventeen patients (68%) had potentially actionable mutations; 4 patients had no mutations detected: 1 post resection; 2 were responding to chemotherapy; 1 was sampled prior to commencing chemotherapy. Genetic alterations detected included: BRAF V600E; KRAS; FGFR; MYC; KIT; PIK3CA and HER2. Twelve patients had ≥ 3 somatic mutations (including variants of uncertain significance (VUS)); ≥ 6 mutations were found in six of these patients.

Conclusions

ctDNA is feasible with an acceptable TAT and the identification of significant potentially actionable targets. Targetable mutations were detected including BRAF, V600E, HER2 and FGFR. Two patients now have access to BRAF and MEK inhibitors. Twelve patients had ≥ 3 mutations that is emerging as potential biomarker of response to immunotherapy. The burden of VUS and presence of actionable targets supports more research on personalised medicine in patients with CUP.

Clinical trial identification

Legal entity responsible for the study

Sarah Cannon Research Institute.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

I. Faull: Employee: Guardant Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.